Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018

Yusupbekov, Abror; Kanda, Mitsuro; Usmanov, Bekhzod; Tuychiev, Otabek; Baymakov, Sayfiddin; Sakamoto, Junichi; Yusupbekov, Akhrorbek

doi:10.31557/APJCP.2020.21.8.2281

Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018

Document Type : Research Articles

Authors

¹ Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology (RSSPMCO&R), Tashkent, Uzbekistan.

² Department of Gastroenterological Surgery (Surgery II), Nagoya University, Graduate School of Medicine, Nagoya, Japan.

³ Surgical Department, Tashkent State Dental Institute, Tashkent, Uzbekistan.

⁴ Tokai Central Hospital, Kakamigahara, Japan.

10.31557/APJCP.2020.21.8.2281

Abstract

Background: Differences in the geographical distributions of esophageal cancer (EC) are associated with environmental influences and genetic risk factors. The inhabitants of the Republic of Uzbekistan are at high-risk for EC; however, detailed epidemiological data regarding the dynamics of EC are not available. Methods: To address this gap in our knowledge, here we reviewed trends in the incidence of EC in Uzbekistan from 2000 through 2018. We acquired the epidemiological data for 17,144 patients with EC from the national epidemiological data base of Uzbekistan. Results: The mean incidence (per 100,000 persons) during the study period was 2.8, which peaked at 3.9 in 2007 and decreased below 2.5 in 2014 and thereafter. The incidence was highest for patients aged 61 years to 70 years (37.5%). Among patients with EC, 13,331 (80.0%) and 3,333 (20.0%) were diagnosed with squamous cell carcinoma or adenocarcinoma, respectively. The incidences of patients with EC with adenocarcinoma were 0.6 from 2010–2018 and 0.4 from 2000 to 2009. The majority of patients were diagnosed with stage III EC, which was associated with a 5-year survival rate that increased from approximately 15% (2000–2009) and plateaued at approximately 25% (2012–2018). Conclusions: We conclude that preventing the progression of EC to stage III is required to improve the prognosis of patients with EC who reside in Uzbekistan.

Keywords

Main Subjects